KORTHOS / ECOSYSTEM / PRODUCT

DEXTER Robotic Surgery System

About

About DEXTER Robotic Surgery System

DEXTER is a mobile, surgeon-controlled robotic system designed to fit existing soft-tissue surgery workflows. Its sterile console keeps the surgeon beside the patient and supports seated or standing operation, while mobile carts carry the robotic arms and can be moved between rooms. The open-architecture endoscope arm accepts 5–10 mm scopes, including 4K fluorescence systems, and the instrument suite uses fully wristed single-use tools.

Distalmotion markets DEXTER in the United States and Europe, with regulatory indications varying by region. US authorization began with adult inguinal-hernia repair in October 2024 and expanded through cholecystectomy, gynecologic procedures and, in August 2026, ventral-hernia repair. Distalmotion reported more than 4,000 patients treated by that latest clearance and positions the compact system particularly for outpatient and ambulatory surgery centres.

Operations

  • Operating Milestone

    Almost 3,000 patients - 2025-11-18 - Europe and United States - DEXTER had treated almost 3,000 patients across Europe and the United States by November 18, 2025.

    Source

Deployments

  • Operating Use

    More than 4,000 patients treated with DEXTER - More than 4,000 patients treated with DEXTER

    Source

Timeline

  • FDA clears DEXTER for ventral hernia repair

    2026-08-13 - Regulatory - The clearance expands DEXTER's U.S. label to the four highest-volume soft-tissue ambulatory procedure categories. Distalmotion reports that surgeons have used DEXTER in more than 4,000 patients. The system is designed for surgeon-controlled robotic assistance within established operating-room workflows.

    Source
  • Distalmotion closes $150M Series G for DEXTER expansion

    2025-11-18 - Funding - The financing also included existing investors and supports clinical and product development. U.S. expansion focuses on ambulatory surgery centres and other outpatient care settings. DEXTER had treated almost 3,000 patients across Europe and the United States when the round was announced.

    Source

Context

Comparable Systems